Summary — SB 2185 (Draft / Senate Amendments)
Bill title (file header): The Students Safe at School Act (note: document text and bill content actually amend the Unified Code of Corrections regarding medications for opioid use disorder)
Main purpose
SB 2185 adds a new Section 3‑6‑2.1 to the Illinois Unified Code of Corrections to require screening, continuation, initiation, and reentry continuity of medications for opioid use disorder (MOUD) for persons committed to Department of Corrections (DOC) institutions and facilities. The goal is to expand access to evidence‑based opioid treatment in correctional settings and to provide continuity of care at release.
Note on procedural/record inconsistency: the provided packet contains conflicting status information. The top of the packet lists the bill as “Died In Committee,” while the legislative actions timeline (detailed below) indicates committee consideration, floor passage, gubernatorial signature and an effective date of 9/1/2025. The substantive summary below is based on the bill text and filed Senate amendments.
Key definitions (from the bill)
- “Clinically indicated” — medical judgment consistent with generally accepted standards of care (as used in the bill).
- “Medication‑assisted treatment (MAT)” — use of FDA‑approved medications combined with counseling and behavioral therapies.
- “Medications for opioid use disorder (MOUD)” — FDA‑approved medications to treat opioid use disorders.
Major provisions
Screening and assessment
- Each committed person must be screened for substance use disorders (including opioid use disorder) as part of an initial and ongoing screening/assessment process.
- The bill’s synopsis and amendment language specify screening within 24 hours of admission and require at least annual assessment ("not less than once per calendar year" appears in amendment text).
Continuation of pre‑admission medications
- If a person is admitted while taking prescribed medications (verified by pharmacy of record, primary care, or prescription monitoring system), that medication shall be continued and provided by the Department pending clinical evaluation by a licensed physician, physician assistant, or nurse practitioner.
- Continuation may only be deferred/discontinued if the evaluating licensed clinician determines continuation is no longer clinically indicated.
Initiation of MOUD in custody
- If a person screens positive for or is diagnosed with opioid use disorder, is at risk, or exhibits withdrawal symptoms, and MOUD is clinically indicated (per a licensed physician/PA/NP), the individual may consent to commence MOUD.
- The Department must provide MOUD immediately and for as long as clinically indicated.
Discontinuation / documentation
- If a licensed clinician discontinues medication, the clinician must document the specific reason in the medical record and provide the individual with oral and written explanation of the decision.
Reentry / continuity of care
- As part of reentry planning, the Department shall commence MOUD prior to release when clinically indicated and with consent.
- The DOC must provide referrals to community‑based providers to support continuation of MOUD and MAT care after release.
Who is affected
- Primary: committed persons incarcerated in Illinois DOC institutions/facilities who have opioid use disorder or are on prescribed medications at admission.
- Secondary: DOC medical and administrative staff, licensed clinicians (physicians, PAs, NPs), community treatment providers, and prescription monitoring systems/pharmacies.
Potential impacts and considerations
- Public health: increased access to evidence‑based treatment in custody and continuity at reentry could reduce withdrawal, overdose risk after release, and recidivism related to untreated opioid use disorder.
- Operational: DOC will need protocols, staff training, medication supply/logistics, pharmacy verification procedures, and referral networks with community providers.
- Costs: increased medical costs for in‑custody medication provision, clinical evaluations, and reentry coordination (offset potentially by public‑health benefits).
- Legal/clinical safeguards: requirement for clinician documentation when discontinuing medications and consent for initiation supports clinical oversight and patient notification.
Procedural/timeline notes (from supplied record)
- Introduced: 2/7/2025 (filed 3/10/2025 per header). Sponsors: Sen. Rachel Ventura (primary), Sen. Adriane Johnson and Sen. Napoleon Harris III (co‑sponsors). Companion: HB 3460.
- Multiple committee actions and amendments filed (Senate Committee Amendments 001 and 002). Committee referrals include Criminal Law and Appropriations — Public Safety & Infrastructure.
- The legislative action log in the packet records committee reports, passage votes in both chambers, a gubernatorial signature on 6/20/2025, and an effective date listed as 9/1/2025 — but the header also states “Died In Committee,” indicating a discrepancy in the provided materials.
Notes on document quality
The amendment and bill texts in the packet contain formatting problems and some garbled sentences. Where language was unclear or fragmented, the summary reflects the clear, repeated policy elements: screening, continuation/initiation of MOUD when clinically indicated, clinician documentation for discontinuation, and reentry referrals.
If you want, I can:
- Produce a short one‑page brief for policymakers focused on costs and implementation steps; or
- Compare the final enrolled language (if available) to this draft to resolve any drafting ambiguities.
